New UK Pathway To Cut Access Times For Breakthrough Products By Up To Four Years
The government’s much heralded response to the UK’s Accelerated Access Review backs proposals such as an accelerated pathway for “transformative” new products, improved horizon scanning, and more flexible commercial arrangements. Former GSK CEO Sir Andrew Witty will chair a new group responsible for selecting products for the new pathway.
You may also be interested in...
Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.
A set of proposals in the recently published Life Sciences Industrial Strategy, aimed at improving the way new products are identified and made available under the NHS, reiterates ideas contained in the 2016 Accelerated Access Review. The government says it will respond to the review shortly.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.